Irbesartan Generis Phar (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors on blood vessels, adrenal glands and renal tubules. This inhibition prevents angiotensin II‑mediated vasoconstriction, aldosterone secretion and sodium‑water retention, leading to vasodilation, reduced blood volume and lower systemic blood pressure.

The dose of Irbesartan Generis Phar is individualized by the prescribing clinician based on the patient’s blood‑pressure goals, renal function and concomitant therapies. The prescriber determines the appropriate starting dose and any subsequent titration according to clinical response and safety monitoring.

Safety of irbesartan during pregnancy has not been established, and the drug is generally avoided unless the potential benefit justifies the risk to the fetus. Limited data are available for breastfeeding; therefore, use is discouraged unless the mother’s condition requires treatment and no safer alternative is available.

To place an order, submit an enquiry on the Irbesartan Generis Phar product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, offering similar blood‑pressure reduction to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly on vascular smooth‑muscle calcium channels, providing complementary mechanisms when combination therapy is needed.

Store Irbesartan Generis Phar at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Irbesartan Generis Phar is taken orally, usually once daily. It can be swallowed with or without food; however, consistent intake with respect to meals helps maintain stable plasma concentrations. Patients should follow the prescriber’s instructions regarding timing and any dose adjustments.

The most serious adverse events to monitor include angio‑edema, acute kidney injury, severe hyperkalemia and significant hypotension. Prompt medical attention is required if swelling of the face, lips or throat occurs, if there is a sudden drop in blood pressure, or if laboratory tests show marked changes in renal function or potassium levels.

Irbesartan is contraindicated in patients with known hypersensitivity to irbesartan or any other ARB. It should also be avoided in individuals with severe hepatic impairment or in those taking aliskiren concurrently if they have diabetes, as this combination increases the risk of adverse renal outcomes.